<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="107499">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01790763</url>
  </required_header>
  <id_info>
    <org_study_id>12-203</org_study_id>
    <nct_id>NCT01790763</nct_id>
  </id_info>
  <brief_title>Compare the Efficacy of Mepilex and Keramatrix in Second Degree Burn Wounds</brief_title>
  <official_title>Prospective,Randomized, Parallel Study to Compare the Efficacy of Mepilex and Keramatrix in Promoting Healing of Second Degree Burn Wounds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas, Galveston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Keraplast Technologies, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shriners Hospitals for Children</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas, Galveston</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the extent to which Keramatrix dressing promotes
      the healing of second-degree burn wounds in pediatric patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Efficacy in promoting wound healing will be determined through comparison to Mepilex, an
      established burn wound dressing.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">October 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Wound Healing</measure>
    <time_frame>Duration of hospital stay, an expected average of 0.75 days per every percent burn  until wound heals</time_frame>
    <safety_issue>No</safety_issue>
    <description>Wound healing will be determined by measuring wound surface area.  Wound surface area will be determined through planimetry, which will be performed on digital photographs of the wounds.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Infection rates</measure>
    <time_frame>Duration of hospital stay, an expected average of 0.75 days per percent burn until wound  heals</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subjects will be monitored for unusual occurences, including signs and symptoms of infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Scarring</measure>
    <time_frame>52 weeks up to 78 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Scarring will be evaluated using the Vancouver Clinical Scar Scale.  Assessments of graft pigmentation, vascularity, pliability and height will be performed at follow-up visits.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>duration of hospital stay, an expected average of 0.75 days per every percent burn  until wound heals, up to 3 times a week during dressing changes</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pain will be assessed using pain scales according to age.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Skin Burn Degree Second</condition>
  <arm_group>
    <arm_group_label>Keramatrix</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Keramatrix</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mepilex</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mepilex</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Keramatrix</intervention_name>
    <description>Dressing for second degree burn</description>
    <arm_group_label>Keramatrix</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mepilex</intervention_name>
    <description>Dressing for second degree wound</description>
    <arm_group_label>Mepilex</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        patient age 0-18 years old Flame or scald burn 10-30% total body surface area burned
        Partial-thickness second-degree burns Admission within 72 hours of burn injury Clean
        non-infected wound as diagnosed by the attending physician

        Exclusion Criteria:

          -  Patient older than 18

          -  Causes other than flame or scald injuries (ie.chemical or frostbite)

          -  Wounds noted to be contaminated or infected

          -  Patients who have received previous treatment efforts (topical dressings or previous
             wound debridement)

          -  Pregnancy lactation

          -  Co-morbidity which may compromise healing: known history of AIDS, ARC, HIV, cancer,
             autoimmune diseases,cirrhosis, tuberculosis, chronic glucocorticoid therapy, diabetes
             mellitus, renal insufficiency, hepatic disease, congestive heart failure prior to
             burn injury, associated severe head injury requiring specific treatment

          -  known allergy to sheep's wool
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Jimenez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cathy Reed, BSN</last_name>
    <phone>409-770-6731</phone>
    <email>ca2reed@utmb.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Deb Benjamin, MSN</last_name>
    <phone>409-770-6731</phone>
    <email>dbenjami@utmb.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shriners Hospitals for Children</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77551</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cathy Reed, BSN</last_name>
      <phone>409-770-6731</phone>
      <email>ca2reed@utmb.edu</email>
    </contact>
    <contact_backup>
      <last_name>Deb Benjamin, MSN</last_name>
      <phone>409-770-6731</phone>
      <email>dbenjami@utmb.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Carlos Jimenez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>David N. Herndon, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 12, 2013</lastchanged_date>
  <firstreceived_date>November 13, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Burn</keyword>
  <keyword>Second-degree</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Burns</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
